Patients presented with diverse breast cancer subtypes (luminal, HER2-positive, triple negative), and were managed with various systemic regimens, including endocrine therapy, CDK4/6 inhibitors chemotherapy, anti-HER2 agents or immune checkpoint inhibitor. This evidence concerns the gene CDK4 and breast cancer.